Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dasotraline for ADHD in children aged 6-12; study completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Dasotraline (dasotraline)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Attention-Deficit Hyperactivity Disorder (ADHD) | Phase 3 | Status: COMPLETED | Results posted: 2020-06-24